Inscripta, a startup that designs and sells gene-editing platforms, raised $150 million in its Series E funding round. The new capital will be used to fund growth, further develop its technology and improve distribution.
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information
that is changing your industry today, hand-curated by our professional editors from
thousands of sources and delivered straight to your inbox.